Adaptive Biotechnologies
NASDAQ: ADPTSeattle, US · Founded 2009 · Washington corporation · 653 employees on LinkedIn · 5 known investors
Find your way into Adaptive Biotechnologies
244 people in our graph share verified history with the Adaptive Biotechnologies team — schools, employers, funds. One of them is your warm intro.
Adam Valkinunlockedknows Harlan Robins · together at Harvard University (overlapped)
.jpeg)
×11knows the team · via Harvard University
Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies. Its Immune Medicine Platform is used to detect, monitor, and treat disease.
Founders & leadership
Adaptive Biotechnologies was founded in 2009 by Chad Robins and Harlan Robins.
CR
Chad RobinsinCEO & Co-Founder
HR
Harlan Robinsinco-founder and chief Scientific Officer2010–2026Harlan Robins co-founded Adaptive Biotechnologies and Harell Data, a cloud services company supporting scientific communities. He previously held roles in the Computational Biology Program at the Fred Hutchinson Cancer Research Center, including Full Member and program head, and holds a BS in Physics from Harvard and a master's and PhD in Physics from UC Berkeley, with postdoctoral work at the Weizmann Institute of Science and the Institute for Advanced Study in Princeton.
KD
Kathleen DetermanninGeneral Counsel, Corporate Secretary, Privacy Officer2014–2016
DS
Dean SchornoinCFO2014–2015
CC
Chris CarlsonExecutive
Board
AL
Arnold LevineBoard director
AZ
Andris ZoltnersBoard director
TW
Tom WillisBoard director
PN
Peter NeupertBoard director
JS
John StuelpnagelBoard director
LH
Lee HuntsmanBoard director
RH
Rob HershbergBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$491.6M disclosed across 4 rounds · 2014–2015
▶$195.1MraisedMay 2015 · 16 investors · BiotechnologyRule 506(b)
▶$195.1MraisedMay 2015 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter NeupertDirector
- Andris ZoltnersDirector
- Tom WillisDirector
- Kathleen DetermannExecutive Officer
- Chad RobinsExecutive Officer, Director
- Rob HershbergDirector
- Dean SchornoExecutive Officer
- John StuelpnagelDirector
- Rob RosenDirector
- Chad CohenDirector
- Arnold LevineDirector
- Offering amount
- $195.1M
- Amount sold
- $195.1M
- First sale
- May 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$93.8MraisedJan 2015 · 4 investors · BiotechnologyRule 506(b)
▶$93.8MraisedJan 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rob RosenDirector
- John StuelpnagelDirector
- Chad RobinsExecutive Officer, Director
- Kathleen DetermannExecutive Officer
- Peter NeupertDirector
- Lee HuntsmanDirector
- Dean SchornoExecutive Officer
- Arnold LevineDirector
- Rob HershbergDirector
- Tom WillisDirector
- Andris ZoltnersDirector
- Offering amount
- $93.8M
- Amount sold
- $93.8M
- First sale
- Jan 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$95.7MraisedJan 2015 · 61 investors · BiotechnologyRule 506(b)
▶$95.7MraisedJan 2015 · 61 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arnold LevineDirector
- Chad RobinsExecutive Officer, Director
- Andris ZoltnersDirector
- Tom WillisDirector
- Kathleen DetermannExecutive Officer
- Peter NeupertDirector
- John StuelpnagelDirector
- Lee HuntsmanDirector
- Rob HershbergDirector
- Rob RosenDirector
- Dean SchornoExecutive Officer
- Offering amount
- $95.7M
- Amount sold
- $95.7M
- First sale
- Jan 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$107MraisedAug 2014 · 6 investors · BiotechnologyRule 506(b)
▶$107MraisedAug 2014 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harlan RobinsExecutive Officer
- Rob HershbergDirector
- Lee HuntsmanDirector
- Rob RosenDirector
- Chris CarlsonExecutive Officer
- Peter NeupertDirector
- Chad RobinsExecutive Officer, Director
- Arnold LevineDirector
- Andris ZoltnersDirector
- Offering amount
- $107M
- Amount sold
- $107M
- First sale
- Apr 2014
- Incorporated
- Corporation, Washington, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Adaptive Biotechnologies went on to found or lead other companies.
In the news
Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.barchart.com · Aug 2026Frequently asked questions
- What does Adaptive Biotechnologies do?
- Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies. Its Immune Medicine Platform is used to detect, monitor, and treat disease.
- Who founded Adaptive Biotechnologies?
- Adaptive Biotechnologies was founded by Chad Robins, Harlan Robins in 2009.
- Who are Adaptive Biotechnologies's investors?
- Adaptive Biotechnologies's investors include Decheng Capital, FMG Capital, Foresite Capital, Khosla Ventures, OrbiMed.
- How much funding has Adaptive Biotechnologies raised?
- Adaptive Biotechnologies has disclosed $491.6M raised across 4 rounds.
- Where is Adaptive Biotechnologies headquartered?
- Adaptive Biotechnologies is headquartered in Seattle, US.